Form 4: Baxter Executive Receives New Equity Grants

Baxter International's Group President, Maria Cecilia Soriano, received new grants of restricted stock units and stock options, alongside a disposition of shares for tax withholding.

Summary

• Maria Cecilia Soriano, Group President, ITT & Pharma. at Baxter International Inc., reported transactions related to her beneficial ownership.
• Acquired 23,742 shares of common stock, representing restricted stock units, on February 27, 2026, with a grant price of $0. These units are scheduled to vest in three equal annual installments beginning on March 1, 2027.
• Disposed of 1,852 shares of common stock on March 2, 2026, at a price of $19.69 per share. This disposition was to cover tax withholding incurred from the settlement of previously vested restricted stock units granted on March 1, 2023.
• Acquired 57,471 stock options on February 27, 2026, with an exercise price of $20.37. These options become exercisable in three equal annual installments beginning on March 1, 2027, and have an expiration date of February 27, 2036.
• Following these reported transactions, Soriano beneficially owns 77,894 shares of common stock and 57,471 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive commitment and standard compensation practices, which are generally well-received by the market as they align management interests with shareholder returns.

Positives

• Maria Cecilia Soriano received a grant of 23,742 restricted stock units, aligning her interests with long-term shareholder value.
• An additional grant of 57,471 stock options was issued, providing further incentive for future performance and retention of key executive talent.

Future Outlook

The newly granted restricted stock units and stock options are scheduled to vest and become exercisable, respectively, in three equal annual installments beginning on March 1, 2027, aligning executive incentives with future company performance and long-term value creation.

Industry Context

StockSavvy.ai notes that equity grants are a standard component of executive compensation packages across the healthcare industry, designed to align management incentives with long-term shareholder value and encourage retention of key leadership.

Comparison to Industry Standards

• The structure of these equity grants, including multi-year vesting schedules for restricted stock units and stock options, is consistent with common executive compensation practices observed in large-cap healthcare companies such as Medtronic (MDT) and Abbott Laboratories (ABT), which typically use similar long-term incentive plans to retain talent and incentivize performance.

Stakeholder Impact

• Shareholders: The equity grants align executive incentives with long-term shareholder value, potentially fostering sustained growth and performance.
• Employees: Reflects standard compensation practices for senior leadership, which can influence overall employee morale and retention strategies within the company.

Next Steps

• First vesting of the 23,742 restricted stock units on March 1, 2027.
• First exercisability of the 57,471 stock options on March 1, 2027.
• Subsequent annual vesting and exercisability installments for both grants will occur on the anniversaries of the first vesting/exercisability date.

Key Dates

Recommendation

This Form 4 details routine executive compensation through equity grants and a tax-related share disposition. Such transactions are standard practice and do not typically indicate a fundamental shift in the company's outlook or performance that would warrant a change from a 'hold' recommendation.

Keywords

Baxter, BAX, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Grants